UBS Michael Yee joins 'Closing Bell Overtime' to talk what could be ahead for M&A in the biotech space.
Biotech remains one of the market's more out-of-favor sectors despite improving industry fundamentals. Here are three stocks trading near multiyear lows.
Jim Cramer says biotech is now the market's hottest group as buyouts accelerate. Here's what's driving the 2026 rally and how ...
Its latest fundraising round provides the French biotech with enough cash to finance operations through 2029.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results